Serum 3-Nitrotyrosine in the Cardiovascular Disease of Patients with Systemic Lupus Erythematosus
3-Nitrotyrosine (3-NT) is a product of tyrosine nitration mediated by reactive nitrogen species such as peroxynitrite anion and nitrogen dioxide. It serves as an indicator of inflammation, cell damage, and nitric oxide production. Systemic lupus erythematosus (SLE) is an autoimmune disorder characte...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/14/6/739 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849435436984827904 |
|---|---|
| author | Juan C. Quevedo-Abeledo Marta Hernández-Díaz María García-González Fuensanta Gómez-Bernal Cristina Almeida-Santiago Elena Heras-Recuero Antonia de Vera-González Alejandra González-Delgado Pedro Abreu-González Beatriz Tejera-Segura Candelaria Martín-González Miguel Á. González-Gay Iván Ferraz-Amaro |
| author_facet | Juan C. Quevedo-Abeledo Marta Hernández-Díaz María García-González Fuensanta Gómez-Bernal Cristina Almeida-Santiago Elena Heras-Recuero Antonia de Vera-González Alejandra González-Delgado Pedro Abreu-González Beatriz Tejera-Segura Candelaria Martín-González Miguel Á. González-Gay Iván Ferraz-Amaro |
| author_sort | Juan C. Quevedo-Abeledo |
| collection | DOAJ |
| description | 3-Nitrotyrosine (3-NT) is a product of tyrosine nitration mediated by reactive nitrogen species such as peroxynitrite anion and nitrogen dioxide. It serves as an indicator of inflammation, cell damage, and nitric oxide production. Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by multisystem involvement and increased oxidative stress. Notably, cardiovascular (CV) disease has emerged as the leading cause of mortality among SLE patients. Our objective was to investigate the association between serum 3-NT levels and a wide range of disease characteristics in patients with SLE, with a particular emphasis on CV comorbidity. A total of 214 patients with SLE were enrolled. The serum levels of 3-NT as well as the activity (SLEDAI) and damage index (SLICC-SDI) scores, full lipid profile, insulin resistance indices, and carotid subclinical atherosclerosis were assessed. Multivariable linear regression analysis was carried out to study the relationship between 3-NT and clinical and laboratory disease characteristics, especially focusing on CV comorbidities. Except for body mass index, which showed a significant positive correlation, the demographic data and traditional CV risk factors did not correlate with 3-NT. After multivariable adjustments, several disease characteristics, including the disease duration, activity and damage indices, and autoantibody profile, showed significant positive associations with 3-NT. Regarding CV characteristics, several lipid profile molecules showed significant relationships with 3-NT. This was not the case for insulin resistance and subclinical atherosclerosis. Remarkably, patients with a high CV risk by SCORE2 showed higher 3-NT values compared to those with a low risk, although after the multivariable adjustment, this relationship was attenuated (but still showed a trend). In conclusion, serum 3-NT levels demonstrated significant positive correlations with multiple disease characteristics, including the disease activity and damage and the autoantibody profile. The lipid pattern in the SLE subjects also significantly and independently correlated with the 3-NT values. Our findings highlight the pathophysiological role of 3-NT specifically, and peroxidation in general, in patients with SLE. |
| format | Article |
| id | doaj-art-e8bca85d2e164e77a951bbc979254229 |
| institution | Kabale University |
| issn | 2076-3921 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj-art-e8bca85d2e164e77a951bbc9792542292025-08-20T03:26:16ZengMDPI AGAntioxidants2076-39212025-06-0114673910.3390/antiox14060739Serum 3-Nitrotyrosine in the Cardiovascular Disease of Patients with Systemic Lupus ErythematosusJuan C. Quevedo-Abeledo0Marta Hernández-Díaz1María García-González2Fuensanta Gómez-Bernal3Cristina Almeida-Santiago4Elena Heras-Recuero5Antonia de Vera-González6Alejandra González-Delgado7Pedro Abreu-González8Beatriz Tejera-Segura9Candelaria Martín-González10Miguel Á. González-Gay11Iván Ferraz-Amaro12Division of Rheumatology, Hospital Doctor Negrín, 35010 Las Palmas de Gran Canaria, SpainDivision of Rheumatology, Hospital Universitario de Canarias, 38320 San Cristóbal de La Laguna, SpainDivision of Rheumatology, Hospital Universitario de Canarias, 38320 San Cristóbal de La Laguna, SpainDivision of Central Laboratory, Hospital Universitario de Canarias, 38320 San Cristóbal de La Laguna, SpainDivision of Rheumatology, Hospital Doctor Negrín, 35010 Las Palmas de Gran Canaria, SpainDivision of Rheumatology, IIS-Fundación Jiménez Díaz, 28040 Madrid, SpainDivision of Central Laboratory, Hospital Universitario de Canarias, 38320 San Cristóbal de La Laguna, SpainDivision of Central Laboratory, Hospital Universitario de Canarias, 38320 San Cristóbal de La Laguna, SpainUnit of Physiology, Department of Basic Medical Sciences, University of La Laguna (ULL), 38200 San Cristóbal de La Laguna, SpainDivision of Rheumatology, Hospital Insular, 35016 Las Palmas de Gran Canaria, SpainDepartment of Internal Medicine, University of La Laguna (ULL), 38200 San Cristóbal de La Laguna, SpainDivision of Rheumatology, IIS-Fundación Jiménez Díaz, 28040 Madrid, SpainDivision of Rheumatology, Hospital Universitario de Canarias, 38320 San Cristóbal de La Laguna, Spain3-Nitrotyrosine (3-NT) is a product of tyrosine nitration mediated by reactive nitrogen species such as peroxynitrite anion and nitrogen dioxide. It serves as an indicator of inflammation, cell damage, and nitric oxide production. Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by multisystem involvement and increased oxidative stress. Notably, cardiovascular (CV) disease has emerged as the leading cause of mortality among SLE patients. Our objective was to investigate the association between serum 3-NT levels and a wide range of disease characteristics in patients with SLE, with a particular emphasis on CV comorbidity. A total of 214 patients with SLE were enrolled. The serum levels of 3-NT as well as the activity (SLEDAI) and damage index (SLICC-SDI) scores, full lipid profile, insulin resistance indices, and carotid subclinical atherosclerosis were assessed. Multivariable linear regression analysis was carried out to study the relationship between 3-NT and clinical and laboratory disease characteristics, especially focusing on CV comorbidities. Except for body mass index, which showed a significant positive correlation, the demographic data and traditional CV risk factors did not correlate with 3-NT. After multivariable adjustments, several disease characteristics, including the disease duration, activity and damage indices, and autoantibody profile, showed significant positive associations with 3-NT. Regarding CV characteristics, several lipid profile molecules showed significant relationships with 3-NT. This was not the case for insulin resistance and subclinical atherosclerosis. Remarkably, patients with a high CV risk by SCORE2 showed higher 3-NT values compared to those with a low risk, although after the multivariable adjustment, this relationship was attenuated (but still showed a trend). In conclusion, serum 3-NT levels demonstrated significant positive correlations with multiple disease characteristics, including the disease activity and damage and the autoantibody profile. The lipid pattern in the SLE subjects also significantly and independently correlated with the 3-NT values. Our findings highlight the pathophysiological role of 3-NT specifically, and peroxidation in general, in patients with SLE.https://www.mdpi.com/2076-3921/14/6/7393-nitrotyrosinesystemic lupus erythematosusdisease damagecardiovascular disease |
| spellingShingle | Juan C. Quevedo-Abeledo Marta Hernández-Díaz María García-González Fuensanta Gómez-Bernal Cristina Almeida-Santiago Elena Heras-Recuero Antonia de Vera-González Alejandra González-Delgado Pedro Abreu-González Beatriz Tejera-Segura Candelaria Martín-González Miguel Á. González-Gay Iván Ferraz-Amaro Serum 3-Nitrotyrosine in the Cardiovascular Disease of Patients with Systemic Lupus Erythematosus Antioxidants 3-nitrotyrosine systemic lupus erythematosus disease damage cardiovascular disease |
| title | Serum 3-Nitrotyrosine in the Cardiovascular Disease of Patients with Systemic Lupus Erythematosus |
| title_full | Serum 3-Nitrotyrosine in the Cardiovascular Disease of Patients with Systemic Lupus Erythematosus |
| title_fullStr | Serum 3-Nitrotyrosine in the Cardiovascular Disease of Patients with Systemic Lupus Erythematosus |
| title_full_unstemmed | Serum 3-Nitrotyrosine in the Cardiovascular Disease of Patients with Systemic Lupus Erythematosus |
| title_short | Serum 3-Nitrotyrosine in the Cardiovascular Disease of Patients with Systemic Lupus Erythematosus |
| title_sort | serum 3 nitrotyrosine in the cardiovascular disease of patients with systemic lupus erythematosus |
| topic | 3-nitrotyrosine systemic lupus erythematosus disease damage cardiovascular disease |
| url | https://www.mdpi.com/2076-3921/14/6/739 |
| work_keys_str_mv | AT juancquevedoabeledo serum3nitrotyrosineinthecardiovasculardiseaseofpatientswithsystemiclupuserythematosus AT martahernandezdiaz serum3nitrotyrosineinthecardiovasculardiseaseofpatientswithsystemiclupuserythematosus AT mariagarciagonzalez serum3nitrotyrosineinthecardiovasculardiseaseofpatientswithsystemiclupuserythematosus AT fuensantagomezbernal serum3nitrotyrosineinthecardiovasculardiseaseofpatientswithsystemiclupuserythematosus AT cristinaalmeidasantiago serum3nitrotyrosineinthecardiovasculardiseaseofpatientswithsystemiclupuserythematosus AT elenaherasrecuero serum3nitrotyrosineinthecardiovasculardiseaseofpatientswithsystemiclupuserythematosus AT antoniadeveragonzalez serum3nitrotyrosineinthecardiovasculardiseaseofpatientswithsystemiclupuserythematosus AT alejandragonzalezdelgado serum3nitrotyrosineinthecardiovasculardiseaseofpatientswithsystemiclupuserythematosus AT pedroabreugonzalez serum3nitrotyrosineinthecardiovasculardiseaseofpatientswithsystemiclupuserythematosus AT beatriztejerasegura serum3nitrotyrosineinthecardiovasculardiseaseofpatientswithsystemiclupuserythematosus AT candelariamartingonzalez serum3nitrotyrosineinthecardiovasculardiseaseofpatientswithsystemiclupuserythematosus AT miguelagonzalezgay serum3nitrotyrosineinthecardiovasculardiseaseofpatientswithsystemiclupuserythematosus AT ivanferrazamaro serum3nitrotyrosineinthecardiovasculardiseaseofpatientswithsystemiclupuserythematosus |